Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.

CNN reports that Pfizer is thinking about launching a clinical test to determine if Chantix can help prevent smokers from having heart attacks. Considering all the negative publicity that has surrounded the drug over the last one and a half years, it’s understandable that Pfizer would want to invest a good deal of time and money in finding some benefit … even if they locate just one slightly dubious side effect, such as a reduced risk of heart attack in people who have quit smoking.

Read the rest of this entry »

It looks like there is another ominous blip in the Chantix radar. Pfizer decided to ditch the ad agency it has been using for its Chantix advertisements. The announcement comes after the company announced the smoking cessation drug’s fourth quarter earnings, which fell 36 percent from the same time last year to $180 million.

Read the rest of this entry »